GlucoMe

Company Overview

Snapshot

Founded in December 2013 by Yiftah Ben Aharon and Dov Moran, GlucoMe operated with 1–10 employees. The company was acquired by CuraLife in January 2021, ceasing operations.

Business overview

GlucoMe developed and marketed a comprehensive digital solution for diabetes management within the Health Tech & Life Sciences sector. Its core technology included an algorithm-based decision-support system that analyzed diabetes data to provide treatment recommendations, forming an autonomous healthcare platform. The solution enabled smart and cost-effective remote care and monitoring, streamlining diabetes management for patients, caregivers, and medical professionals. The platform integrated individual patient and population management, featuring an affordable wireless blood glucose monitor with patented audio connectivity, a mobile app, a cloud-based Digital Diabetes Clinic, and a Control Tower for data-driven prioritization and management. GlucoMe operated in sectors such as Digital Healthcare, Medical Decision Support, and Patient Remote Monitoring, serving patients and providers globally.

Strategic signal

In June 2019, GlucoMe received CE Mark approval for its diabetes decision support technology. This regulatory milestone was critical for validating the safety and performance of its digital diabetes management platform, enabling broader market access within Europe and signaling to investors the company's progress in meeting international medical device standards.

Company Intelligence Q&A

What is GlucoMe's primary focus?

GlucoMe focuses on developing a comprehensive digital solution for diabetes management, utilizing an algorithm-based decision-support system to analyze diabetes data and provide treatment recommendations.

When was GlucoMe founded and by whom?

GlucoMe was founded in December 2013 by Yiftah Ben Aharon and Dov Moran.

What was a significant regulatory achievement for GlucoMe?

In June 2019, GlucoMe obtained CE Mark approval for its diabetes decision support technology, enabling its use in European markets.

What was the outcome for GlucoMe?

GlucoMe was acquired by CuraLife in January 2021 and subsequently ceased to operate.

Did GlucoMe engage in any international partnerships?

In August 2018, Merck KGaA and GlucoMe partnered to pilot remote, digital diabetes care in Vietnam. Additionally, in April 2018, GlucoMe and DiaMan announced the market launch of GlucoMe's digital diabetes care solution in Central America.